Stockhead: Racura Oncology opens Hong Kong site in “cautious” trial rollout

Stockhead‘s Tim Boreham has reported on Racura Oncology announcing the site activation of Queen Mary Hospital in Hong Kong, enabling the commencement of patient recruitment for Phase 1 clinical trial of RC220 in combination with doxorubicin in advanced solid tumour patients. The company hopes that as well as attacking the tumours, RC220 will protect the heart against the dangerous effects of chemotherapy.

Read the full article here.

Latest Posts

L36, 1 Macquarie Place Sydney NSW 2000
E: info@racuraoncology.com T: +61 2 8051 3043
© 2026 Racura Oncology | Privacy Policy
Sign up to receive the most recent news and updates
Sign up to receive the most recent news and updates
Racura Oncology
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.